Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation.

CONTEXT Germline AIP mutations usually cause young-onset acromegaly with low penetrance in a subset of familial isolated pituitary adenoma families. We describe our experience with a large family with R304* AIP mutation and discuss some of the diagnostic dilemmas and management issues. OBJECTIVE The aim of the study was to identify and screen mutation carriers in the family. PATIENTS Forty-three family members participated in the study. SETTING The study was performed in university hospitals. OUTCOME We conducted genetic and endocrine screening of family members. RESULTS We identified 18 carriers of the R304* mutation, three family members with an AIP-variant A299V, and two family members who harbored both changes. One of the two index cases presented with gigantism and pituitary apoplexy, the other presented with young-onset acromegaly, and both had surgery and radiotherapy. After genetic and clinical screening of the family, two R304* carriers were diagnosed with acromegaly. They underwent transsphenoidal surgery after a short period of somatostatin analog treatment. One of these two patients is in remission; the other achieved successful pregnancy despite suboptimal control of acromegaly. One of the A299V carrier family members was previously diagnosed with a microprolactinoma; we consider this case to be a phenocopy. Height of the unaffected R304* carrier family members is not different compared to noncarrier relatives. CONCLUSIONS Families with AIP mutations present particular problems such as the occurrence of large invasive tumors, poor response to medical treatment, difficulties with fertility and management of pregnancy, and the finding of AIP sequence variants of unknown significance. Because disease mostly develops at a younger age and penetrance is low, the timing and duration of the follow-up of carriers without overt disease requires further study. The psychological and financial impact of prolonged clinical screening must be considered. Excellent relationships between the family, endocrinologists, and geneticists are essential, and ideally these families should be managed in centers with specialist expertise.

[1]  P. Kadıoğlu,et al.  Familial acromegaly due to aryl hydrocarbon receptor-interacting protein (AIP) gene mutation in a Turkish cohort , 2014, Pituitary.

[2]  G. Chrousos,et al.  Familial pituitary apoplexy as the only presentation of a novel AIP mutation. , 2013, Endocrine-related cancer.

[3]  V. Esposito,et al.  Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. , 2013, Endocrine-related cancer.

[4]  M. Korbonits,et al.  Novel pathway for somatostatin analogs in patients with acromegaly , 2013, Trends in Endocrinology & Metabolism.

[5]  Jennifer D. Brooks,et al.  Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Aaltonen,et al.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. , 2013, Endocrine reviews.

[7]  D. Horn,et al.  BRCA1/2 testing: uptake, phenocopies, and strategies to improve detection rates in initially negative families , 2012, Clinical genetics.

[8]  M. Korbonits,et al.  Familial pituitary adenomas – who should be tested for AIP mutations? , 2012, Clinical endocrinology.

[9]  M. Korbonits,et al.  Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. , 2012, The Journal of clinical endocrinology and metabolism.

[10]  P. Chanson,et al.  Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. , 2012, The Journal of clinical endocrinology and metabolism.

[11]  S. Ezzat,et al.  Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature , 2012, Clinical endocrinology.

[12]  Anita Singh,et al.  Management of prolactinoma with cabergoline treatment in a pregnant woman during her entire pregnancy , 2011, Indian journal of endocrinology and metabolism.

[13]  M. Armoni,et al.  Uneventful octreotide LAR therapy throughout three pregnancies, with favorable delivery and anthropometric measures for each newborn: a case report , 2011, Journal of medical case reports.

[14]  M. Junier,et al.  Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. , 2011, Endocrine-related cancer.

[15]  Richard L. Abel,et al.  AIP mutation in pituitary adenomas in the 18th century and today. , 2011, The New England journal of medicine.

[16]  R. Paschke,et al.  Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. , 2010, The Journal of clinical endocrinology and metabolism.

[17]  V. Bours,et al.  The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes , 2010, Clinical genetics.

[18]  P. Chanson,et al.  Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. , 2010, The Journal of clinical endocrinology and metabolism.

[19]  A. Paetau,et al.  Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. , 2010, The American journal of pathology.

[20]  P. Bernard,et al.  Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women , 2010, Clinical endocrinology.

[21]  M. Korbonits,et al.  Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA) , 2010, Trends in Endocrinology & Metabolism.

[22]  E. Menis,et al.  The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or founder effect? , 2010, Journal of endocrinological investigation.

[23]  Alberto Fernández,et al.  Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) , 2010, Clinical endocrinology.

[24]  T. Arzberger,et al.  Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly , 2009, International journal of cancer.

[25]  B. Teh,et al.  Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma. , 2009, Endocrine-related cancer.

[26]  Julian R. E. Davis,et al.  The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. , 2008, The Journal of clinical endocrinology and metabolism.

[27]  Youngsook Lee,et al.  Deletion of the Aryl Hydrocarbon Receptor-associated Protein 9 Leads to Cardiac Malformation and Embryonic Lethality* , 2007, Journal of Biological Chemistry.

[28]  V. Bours,et al.  Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. , 2007, European journal of endocrinology.

[29]  S. Weinzimer,et al.  Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. , 2007, The Journal of clinical endocrinology and metabolism.

[30]  B. Estour,et al.  Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. , 2007, The Journal of clinical endocrinology and metabolism.

[31]  A. Beckers,et al.  High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. , 2006, The Journal of clinical endocrinology and metabolism.

[32]  G. Ramanathan,et al.  IVF/ICSI in a woman with active acromegaly: Successful outcome following treatment with pegvisomant , 2006, Journal of Assisted Reproduction and Genetics.

[33]  R. Paschke,et al.  Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene , 2006, Science.

[34]  Shereen Ezzat,et al.  The prevalence of pituitary adenomas , 2004, Cancer.

[35]  M. Fassnacht,et al.  Octreotide LAR® treatment throughout pregnancy in an acromegalic woman , 2001, Clinical endocrinology.

[36]  Jelliffe..  The Pituitary Body and its Disorders. Clinical States Produced by Disorders of the Hypophysis Cerebri , 1912 .

[37]  A. Keith.  AN INQUIRY INTO THE NATURE OF THE SKELETAL CHANGES IN ACROMEGALY. , 1911 .

[38]  M. Dattania,et al.  Characterization of aryl hydrocarbon receptor-interacting protein ( AIP ) mutations in familial isolated pituitary adenoma families , 2011 .

[39]  W. Ludlam.  Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline , 2011 .

[40]  M. Korbonits,et al.  AIP mutation in pituitary adenomas , 2011 .

[41]  B. Estour,et al.  Clinical characterization of familial isolated pituitary adenomas. , 2006, The Journal of clinical endocrinology and metabolism.

[42]  高野 浩一.  Normal development of the pituitary gland : Assessment with three-dimensional MR volumetry , 2000 .